FR2125309B1 - - Google Patents

Info

Publication number
FR2125309B1
FR2125309B1 FR7203470A FR7203470A FR2125309B1 FR 2125309 B1 FR2125309 B1 FR 2125309B1 FR 7203470 A FR7203470 A FR 7203470A FR 7203470 A FR7203470 A FR 7203470A FR 2125309 B1 FR2125309 B1 FR 2125309B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7203470A
Other versions
FR2125309A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of FR2125309A1 publication Critical patent/FR2125309A1/fr
Application granted granted Critical
Publication of FR2125309B1 publication Critical patent/FR2125309B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7203470A 1971-02-16 1972-02-02 Expired FR2125309B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11587871A 1971-02-16 1971-02-16
US25664172A 1972-05-25 1972-05-25

Publications (2)

Publication Number Publication Date
FR2125309A1 FR2125309A1 (fr) 1972-09-29
FR2125309B1 true FR2125309B1 (fr) 1976-05-14

Family

ID=26813670

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7203470A Expired FR2125309B1 (fr) 1971-02-16 1972-02-02

Country Status (9)

Country Link
US (2) US3700681A (fr)
AT (1) AT315842B (fr)
BE (1) BE778771A (fr)
CA (1) CA978962A (fr)
CH (1) CH541560A (fr)
DE (2) DE2204195C2 (fr)
FR (1) FR2125309B1 (fr)
GB (2) GB1367669A (fr)
NL (1) NL174349C (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR207639A1 (es) * 1973-12-26 1976-10-22 Pfizer Un procedimiento para preparar pirido (3,2-d)1,3-dioxin-6-epoxietanos y compuestos intermediarios desprovistos de actividad terapeutica
US3952101A (en) * 1975-04-14 1976-04-20 Smithkline Corporation α-Amino methyl-5-hydroxy-2-pyridinemethanols
US4011231A (en) * 1975-10-03 1977-03-08 Pfizer Inc. 2-Phenyl-6-(1-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin maleate and its use as an intermediate
SE7708307L (sv) * 1976-08-26 1978-02-27 Pfizer Forfarande for framstellning av farmaceutiska kompositioner anvendbara sasom bronkodilatorer
US4175128A (en) * 1979-01-03 1979-11-20 Pfizer Inc. Method for treating congestive heart failure
SU1194273A3 (ru) * 1981-02-09 1985-11-23 Пфайзер Инк (Фирма) Способ получени пирбутерола или его аналогов
US4632992A (en) * 1981-02-09 1986-12-30 Pfizer Inc. Intermediates for preparing pirbuterol and analogs
GB8414559D0 (en) * 1984-06-07 1984-07-11 Scras Pyridine derivatives
EP0220054A3 (fr) * 1985-10-16 1987-12-02 Glaxo Group Limited Dérivés d'éthanolamine
US4601897A (en) * 1985-11-06 1986-07-22 Pfizer Inc. Prazosin-pirbuterol combination for bronchodilation
AU2305092A (en) * 1991-06-26 1993-01-25 Sepracor, Inc. Methods and compositions for treating pulmonary and cardiac disorders using optically pure (+) pirbuterol
AU2270092A (en) * 1991-06-26 1993-01-25 Sepracor, Inc. Methods and compositions for treating pulmonary and cardiac disorders using optically pure (-)pirbuterol
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
EP1663999A2 (fr) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibiteurs de la phosphodiesterase de type iv
WO2005051931A2 (fr) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase
WO2005092860A1 (fr) * 2004-03-23 2005-10-06 Pfizer Limited Composes servant au traitement de maladies
EP1934219A1 (fr) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
JP2009512676A (ja) 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体アンタゴニストの医薬組成物
RU2008119322A (ru) * 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Композиции ингибиторов фосфодиэстеразы iv типа
ES2397284T3 (es) 2006-08-22 2013-03-06 Ranbaxy Laboratories Limited Proceso para preparar inhibidores de la metaloproteinasa de la matriz y auxiliares quirales para los mismos
AU2007298549A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
WO2008035316A2 (fr) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibiteurs de phosphodiestérase
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
WO2008111009A1 (fr) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Dérivés de pyrazolo[3,4-b]pyridine comme inhibiteurs de phosphodiestérases
MX2009009793A (es) * 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
EP2111861A1 (fr) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
CN103119030A (zh) 2010-07-30 2013-05-22 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
CN103228634A (zh) 2010-09-24 2013-07-31 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
CN103848781B (zh) * 2012-11-30 2017-06-30 重庆华邦制药有限公司 高选择性氧化二羟甲基吡啶中一个羟甲基的方法
DK2925725T3 (en) 2012-12-03 2017-01-16 Pfizer androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1089189A (en) * 1964-09-23 1967-11-01 Koninklijke Pharma Fab Nv Ethers of -(2-pyridyl)benzyl alcohols

Also Published As

Publication number Publication date
GB1367668A (en) 1974-09-18
AT315842B (de) 1974-06-10
DE2204195A1 (de) 1972-08-17
FR2125309A1 (fr) 1972-09-29
US3700681A (en) 1972-10-24
DE2265581C2 (de) 1982-07-01
GB1367669A (en) 1974-09-18
US3763173A (en) 1973-10-02
CA978962A (en) 1975-12-02
NL174349B (nl) 1984-01-02
BE778771A (fr) 1972-08-01
CH541560A (fr) 1973-10-31
NL174349C (nl) 1984-06-01
NL7201471A (fr) 1972-08-18
DE2204195C2 (de) 1981-11-19

Similar Documents

Publication Publication Date Title
ATA136472A (fr)
AU2658571A (fr)
AU2691671A (fr)
AU2485671A (fr)
AU3005371A (fr)
AU2952271A (fr)
AU2941471A (fr)
AU2894671A (fr)
AU2742671A (fr)
AU2684071A (fr)
AU2564071A (fr)
AU2684171A (fr)
AU2907471A (fr)
AU2473671A (fr)
AU2486471A (fr)
AU3025871A (fr)
AU2503871A (fr)
AU2456871A (fr)
AU2577671A (fr)
AU2588771A (fr)
AU2654071A (fr)
AR192311Q (fr)
AU2669471A (fr)
AU2415871A (fr)
AR199640Q (fr)

Legal Events

Date Code Title Description
CC Supplementary protection certificate (spc) laid open to the public (law of 25 june 1990)

Free format text: 92C0009, 920130

CB Supplementary protection certificate (spc) granted (law of 25 june 1990)

Free format text: 92C0009, 720202

CP Supplementary protection certificate (spc) filed